Your session is about to expire
← Back to Search
Cancer Vaccine for Ovarian Cancer
Study Summary
This trial is testing a new cancer vaccine made from a person's own dendritic cells. Dendritic cells are powerful immune cells that help the body fight infections. The vaccine will be given with laboratory made agents GM-CSF and imiquimod. Researchers want to see if the vaccine is safe and if it has any effect on the person's cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer responded completely to initial or second-line chemotherapy.I have advanced or recurrent ovarian, fallopian tube, or peritoneal cancer without disease progression.I can care for myself and am expected to live more than six weeks.My severe side effects from chemotherapy have gone away.My disease is stable and does not need chemotherapy before starting vaccination.It's been less than 12 weeks since my last chemotherapy dose.I have never had a serious blood clot.Your white blood cell count, platelet count, bilirubin, creatinine, and liver enzymes are within certain healthy ranges.I do not have an autoimmune disease that needs treatment with immunosuppressants.I am not pregnant or breastfeeding and will use birth control during the study.My cancer got worse while on first-line platinum/taxane chemotherapy.I do not have a serious illness like an infection needing IV antibiotics or major heart problems.I have another cancer besides skin cancer that is not being treated to cure it or was diagnosed in the last 2 years.I had surgery to reduce my tumor size and my tissue was stored for study.
- Group 1: Group 2
- Group 2: Group 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are currently partaking in this medical research?
"No longer seeking participants, this research was first posted on August 1st 2008 and last edited on January 25th 2022. If you are exploring other medical studies, presently there 694 active trials accepting patients with fallopian tubes cancer and 21 clinical investigations looking for volunteers to receive a Dendritic Cell/Tumor Fusion Vaccine."
What potential risks do patients face when utilizing Dendritic Cell/Tumor Fusion Vaccine?
"We have assigned Dendritic Cell/Tumor Fusion Vaccine a score of 2, as the available evidence suggests it is safe but efficacy data has yet to be produced."
Have any other investigations explored the efficacy of Dendritic Cell/Tumor Fusion Vaccine?
"Presently, 21 clinical trials for Dendritic Cell/Tumor Fusion Vaccine are taking place. 5 of these investigations have progressed to the Phase 3 stage. Locations offering this therapy span 84 different sites, with most being located in Houston, Texas."
What maladies can be remedied with the Dendritic Cell/Tumor Fusion Vaccine?
"Dendritic Cell/Tumor Fusion Vaccine is effective at treating scalp structure, condylomata acuminata, and facial lesions."
Is it possible for new participants to join this clinical trial?
"This medical trial is no longer accepting new participants. It was first posted on August 1st, 2008 and the most recent update to its information occurred on January 25th, 2022. If searching for other studies, 694 clinical trials are actively looking for patients with fallopian tubes cancer while 21 of them seek persons interested in joining a Dendritic Cell/Tumor Fusion Vaccine study."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger